152 related articles for article (PubMed ID: 19850535)
1. The role of dose escalation with intracavitary brachytherapy in the treatment of localized CNS malignancies: outcomes and toxicities of a prospective study.
Wernicke AG; Sherr DL; Schwartz TH; Pannullo SC; Stieg PE; Boockvar JA; Moliterno JA; Ivanidze J; Trichter S; Sabbas AM; Parashar B; Nori D
Brachytherapy; 2010; 9(1):91-9. PubMed ID: 19850535
[TBL] [Abstract][Full Text] [Related]
2. Feasibility and safety of GliaSite brachytherapy in treatment of CNS tumors following neurosurgical resection.
Wernicke AG; Sherr DL; Schwartz TH; Pannullo SC; Stieg PE; Boockvar JA; Ivanidze J; Moliterno JA; Parashar B; Trichter S; Sabbas AM; Nori D
J Cancer Res Ther; 2010; 6(1):65-74. PubMed ID: 20479550
[TBL] [Abstract][Full Text] [Related]
3. Treatment of recurrent glioblastoma multiforme with GliaSite brachytherapy.
Chan TA; Weingart JD; Parisi M; Hughes MA; Olivi A; Borzillary S; Alahakone D; Detorie NA; Wharam MD; Kleinberg L
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):1133-9. PubMed ID: 15990019
[TBL] [Abstract][Full Text] [Related]
4. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
5. GliaSite brachytherapy boost as part of initial treatment of glioblastoma multiforme: a retrospective multi-institutional pilot study.
Welsh J; Sanan A; Gabayan AJ; Green SB; Lustig R; Burri S; Kwong E; Stea B
Int J Radiat Oncol Biol Phys; 2007 May; 68(1):159-65. PubMed ID: 17331666
[TBL] [Abstract][Full Text] [Related]
6. An inflatable balloon catheter and liquid 125I radiation source (GliaSite Radiation Therapy System) for treatment of recurrent malignant glioma: multicenter safety and feasibility trial.
Tatter SB; Shaw EG; Rosenblum ML; Karvelis KC; Kleinberg L; Weingart J; Olson JJ; Crocker IR; Brem S; Pearlman JL; Fisher JD; Carson K; Grossman SA;
J Neurosurg; 2003 Aug; 99(2):297-303. PubMed ID: 12924704
[TBL] [Abstract][Full Text] [Related]
7. GliaSite brachytherapy for treatment of recurrent malignant gliomas: a retrospective multi-institutional analysis.
Gabayan AJ; Green SB; Sanan A; Jenrette J; Schultz C; Papagikos M; Tatter SP; Patel A; Amin P; Lustig R; Bastin KT; Watson G; Burri S; Stea B
Neurosurgery; 2006 Apr; 58(4):701-9; discussion 701-9. PubMed ID: 16575334
[TBL] [Abstract][Full Text] [Related]
8. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
9. Imaging after GliaSite brachytherapy: prognostic MRI indicators of disease control and recurrence.
Kleinberg L; Yoon G; Weingart JD; Parisi M; Olivi A; Detorie NA; Chan TA
Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1385-91. PubMed ID: 19394153
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant fractionated high-dose-rate intracavitary brachytherapy after external beam radiotherapy in Tl and T2 nasopharyngeal carcinoma.
Lu JJ; Shakespeare TP; Tan LK; Goh BC; Cooper JS
Head Neck; 2004 May; 26(5):389-95. PubMed ID: 15122654
[TBL] [Abstract][Full Text] [Related]
11. Five-year results: the initial clinical trial of MammoSite balloon brachytherapy for partial breast irradiation in early-stage breast cancer.
Benitez PR; Keisch ME; Vicini F; Stolier A; Scroggins T; Walker A; White J; Hedberg P; Hebert M; Arthur D; Zannis V; Quiet C; Streeter O; Silverstein M
Am J Surg; 2007 Oct; 194(4):456-62. PubMed ID: 17826055
[TBL] [Abstract][Full Text] [Related]
12. Accelerated partial breast irradiation: an analysis of variables associated with late toxicity and long-term cosmetic outcome after high-dose-rate interstitial brachytherapy.
Wazer DE; Kaufman S; Cuttino L; DiPetrillo T; Arthur DW
Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):489-95. PubMed ID: 16246495
[TBL] [Abstract][Full Text] [Related]
13. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
[TBL] [Abstract][Full Text] [Related]
14. Preliminary results and evaluation of MammoSite balloon brachytherapy for partial breast irradiation for pure ductal carcinoma in situ: a phase II clinical study.
Benitez PR; Streeter O; Vicini F; Mehta V; Quiet C; Kuske R; Hayes MK; Arthur D; Kuerer H; Freedman G; Keisch M; Dipetrillo T; Khan D; Hudes R
Am J Surg; 2006 Oct; 192(4):427-33. PubMed ID: 16978943
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcome and toxicity in a Phase I/II trial using high-dose-rate multicatheter interstitial brachytherapy for T1/T2 breast cancer.
Kaufman SA; DiPetrillo TA; Price LL; Midle JB; Wazer DE
Brachytherapy; 2007; 6(4):286-92. PubMed ID: 17991625
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of radiation dose escalation with conformal external beam radiotherapy and high-dose-rate brachytherapy combined with long-term androgen suppression in unfavorable prostate cancer: feasibility report.
Valero J; Cambeiro M; Galán C; Teijeira M; Romero P; Zudaire J; Moreno M; Ciérvide R; Aristu JJ; Martínez-Monge R
Int J Radiat Oncol Biol Phys; 2010 Feb; 76(2):386-92. PubMed ID: 19427741
[TBL] [Abstract][Full Text] [Related]
17. High-dose-rate interstitial brachytherapy for gynecologic malignancies.
Beriwal S; Bhatnagar A; Heron DE; Selvaraj R; Mogus R; Kim H; Gerszten K; Kelley J; Edwards RP
Brachytherapy; 2006; 5(4):218-22. PubMed ID: 17118313
[TBL] [Abstract][Full Text] [Related]
18. Partial breast irradiation with interstitial 60CO brachytherapy results in frequent grade 3 or 4 toxicity. Evidence based on a 12-year follow-up of 70 patients.
Póti Z; Nemeskéri C; Fekésházy A; Sáfrány G; Bajzik G; Nagy ZP; Bidlek M; Sinkovics I; Udvarhelyi N; Liszkay G; Repa I; Galuska L; Trón L; Mayer A; Esik O
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1022-33. PubMed ID: 15001241
[TBL] [Abstract][Full Text] [Related]
19. High-dose-rate interstitial brachytherapy in recurrent and previously irradiated head and neck cancers--preliminary results.
Narayana A; Cohen GN; Zaider M; Chan K; Lee N; Wong RJ; Boyle J; Shaha A; Kraus D; Shah J; Zelefsky MJ
Brachytherapy; 2007; 6(2):157-63. PubMed ID: 17434110
[TBL] [Abstract][Full Text] [Related]
20. Results of a phase II trial of the GliaSite radiation therapy system for the treatment of newly diagnosed, resected single brain metastases.
Rogers LR; Rock JP; Sills AK; Vogelbaum MA; Suh JH; Ellis TL; Stieber VW; Asher AL; Fraser RW; Billingsley JS; Lewis P; Schellingerhout D; Shaw EG;
J Neurosurg; 2006 Sep; 105(3):375-84. PubMed ID: 16961129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
